The combination of a c-MET inhibitor and the EGF-R inhibitor erlotinib was used compared to using either inhibitor alone in the NSCLC tumor xenograft mice model and indicated a significant anti-tumor function [258]. Here, MET is linked to non-small cell lung carcinoma.